122 related articles for article (PubMed ID: 8032079)
1. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma.
Elba S; Giannuzzi V; Misciagna G; Manghisi OG
Ital J Gastroenterol; 1994 Mar; 26(2):66-8. PubMed ID: 8032079
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial.
Manesis EK; Giannoulis G; Zoumboulis P; Vafiadou I; Hadziyannis SJ
Hepatology; 1995 Jun; 21(6):1535-42. PubMed ID: 7768497
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma.
Barbare JC; Bouché O; Bonnetain F; Raoul JL; Rougier P; Abergel A; Boige V; Denis B; Blanchi A; Pariente A; Milan C; Bedenne L
J Clin Oncol; 2005 Jul; 23(19):4338-46. PubMed ID: 15994145
[TBL] [Abstract][Full Text] [Related]
4. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial.
Chow PK; Tai BC; Tan CK; Machin D; Win KM; Johnson PJ; Soo KC;
Hepatology; 2002 Nov; 36(5):1221-6. PubMed ID: 12395333
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study.
Liu CL; Fan ST; Ng IO; Lo CM; Poon RT; Wong J
Am J Gastroenterol; 2000 Jan; 95(1):218-22. PubMed ID: 10638587
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen.
Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire
Hepatology; 2004 Dec; 40(6):1361-9. PubMed ID: 15565568
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
Pan DY; Qiao JG; Chen JW; Huo YC; Zhou YK; Shi HA
Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):211-5. PubMed ID: 14599971
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma.
Chow PK
Cancer Treat Rev; 2005 Oct; 31(6):491-5. PubMed ID: 16214294
[No Abstract] [Full Text] [Related]
9. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
[TBL] [Abstract][Full Text] [Related]
10. [Randomized trial of elliptinium acetate and tamoxifen in the treatment of inoperable hepatocellular carcinoma].
Jouanolle H; Delamaire D; Deugnier Y; Lhéry D; Simon M; Brissot P; Bourel M
Gastroenterol Clin Biol; 1986 Feb; 10(2):185-7. PubMed ID: 3009255
[No Abstract] [Full Text] [Related]
11. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
12. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).
Doffoël M; Bonnetain F; Bouché O; Vetter D; Abergel A; Fratté S; Grangé JD; Stremsdoerfer N; Blanchi A; Bronowicki JP; Caroli-Bosc FX; Causse X; Masskouri F; Rougier P; Bedenne L;
Eur J Cancer; 2008 Mar; 44(4):528-38. PubMed ID: 18242076
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
14. Treatment with all-trans retinoic acid plus tamoxifen and vitamin E in advanced hepatocellular carcinoma.
Clerici C; Castellani D; Russo G; Fiorucci S; Sabatino G; Giuliano V; Gentili G; Morelli O; Raffo P; Baldoni M; Morelli A; Toma S
Anticancer Res; 2004; 24(2C):1255-60. PubMed ID: 15154656
[TBL] [Abstract][Full Text] [Related]
15. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma.
Melia WM; Johnson PJ; Williams R
Cancer Treat Rep; 1987 Dec; 71(12):1213-6. PubMed ID: 2446752
[TBL] [Abstract][Full Text] [Related]
16. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
Yuen MF; Poon RT; Lai CL; Fan ST; Lo CM; Wong KW; Wong WM; Wong BC
Hepatology; 2002 Sep; 36(3):687-91. PubMed ID: 12198662
[TBL] [Abstract][Full Text] [Related]
17. [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
Lim TY; Cheong JY; Cho SW; Sim SJ; Kim JS; Choi SJ; Choi JW; Kwon HC; Lee KM; Kim JK; Won JH; Yoo BM; Lee KJ; Hahm KB; Kim JH
Korean J Hepatol; 2006 Mar; 12(1):65-73. PubMed ID: 16565607
[TBL] [Abstract][Full Text] [Related]
18. [Retrospective analysis of clinical results in eight patients with advanced hepatocellular carcinoma with lung metastases treated by TS-1].
Nagata H; Hatano E; Asechi H; Narita M; Yanagida A; Yasuchika K; Ikai I; Uemoto S
Gan To Kagaku Ryoho; 2007 Feb; 34(2):233-5. PubMed ID: 17301534
[TBL] [Abstract][Full Text] [Related]
19. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.
Gish RG; Porta C; Lazar L; Ruff P; Feld R; Croitoru A; Feun L; Jeziorski K; Leighton J; Gallo J; Kennealey GT
J Clin Oncol; 2007 Jul; 25(21):3069-75. PubMed ID: 17634485
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
